Ginkgo Bioworks Holdings Inc vs Hershey Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Hershey Co trades at $162.36 (market cap $32.66B). The key difference: Hershey Co is far larger — about 42.8× Ginkgo Bioworks Holdings Inc's market cap, and Hershey Co pays a 3.57% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Hershey Co for 135 Days on average.
| DNA | HSY | |
|---|---|---|
Market Cap | $763.64M | $32.66B |
Volume | 3,204,177 | 1,578,237 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $236.28 |
52-Week Low | $5.48 | $157.61 |
Typical Hold Time | 7 Days | 135 Days |
Enterprise Value | $865.59M | $37.79B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Hershey (HSY) trades at $161.88, up 0.96% with a bearish technical outlook. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though Q3 2026 earnings are pending. Recent news highlights brand investments and dividend resumption after a near 2-year freeze. Valuation metrics include P/E of 22.2 and P/S of 2.72, with analyst consensus price target at $204.62 representing 26% upside potential.
HSY presents a mixed investment case with strong fundamentals offset by near-term headwinds. The opportunity lies in consistent dividend growth potential and market leadership, while risks include commodity cost pressures and competitive challenges. Analyst sentiment leans cautious with 66% hold ratings, suggesting patience for earnings catalysts and margin stabilization.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →